Network meta-analysis of 16 RCTs (2,034 patients) of eight monoclonal antibodies vs placebo for chronic rhinosinusitis with nasal polyps: all reduced nasal polyp score, stapokibart ranking first; adverse event risk was comparable to placebo for all.
Meta-analysisn = 2,034
Wang et al. Targeted biologics for chronic rhinosinusitis with nasal polyps: efficacy and safety comparison of eight monoclonal antibodies via network meta-analysis